MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317586 | Name: Deferoxamine mesylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deferoxamine is a bacterial siderophore produced by the Actinobacteria Streptomyces pilosus. It has medical applications as a chelating agent used to remove excess iron from the body. The mesylate salt of DFO-B is commercially available. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. Deferoxamine acts by binding free iron in the bloodstream and enhancing its elimination in the urine.

Chemical Structure

Deferoxamine mesylate
Deferoxamine mesylate
CAS#138-14-7 (mesylate)

Theoretical Analysis

MedKoo Cat#: 317586

Name: Deferoxamine mesylate

CAS#: 138-14-7 (mesylate)

Chemical Formula: C26H52N6O11S

Exact Mass: 560.3534

Molecular Weight: 656.79

Elemental Analysis: C, 47.55; H, 7.98; N, 12.80; O, 26.80; S, 4.88

Price and Availability

Size Price Availability Quantity
1g USD 450.00 2 Weeks
2g USD 750.00 2 Weeks
5g USD 1,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
70-51-9 (free base) 1950-39-6 (HCl) 138-14-7 (mesylate) 25442-95-9 (hydrate)
Synonym
Deferoxamine mesilate; Deferoxamine; Deferoxaminum; Deferoxamin; Desferin; Deferrioxamine B; DFOA; Desferal; Ba 33112; Ba-33112; Ba33112;DFOM; DFX; NSC 644468; NSC-644468; NSC644468;
IUPAC/Chemical Name
N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-butanediamide, monomethanesulfonate
InChi Key
IDDIJAWJANBQLJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
SMILES Code
O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O.CS(=O)(O)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C21M05C25
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Deferoxamine mesylate is an iron chelator that binds free iron in a stable complex, preventing it from engaging in chemical reactions.
In vitro activity:
To explore the underlying mechanism of the effect of DFO on K562 cells, the expression of apoptosis-related genes Bax, p53, and Fas were assessed by Western blotting and qRT-PCR, respectively. As expected, it was found that the protein (Figure 3) and mRNA (Figure 4) levels of Bax, p53, and Fas were dose-dependently increased in DFO-treated K562 cells, while the level of Bcl-2 markedly decreased in a dose-dependent manner. These results suggest that DFO plays a protective role in leukemia by inhibiting leukemia cell viability and inducing cell apoptosis via regulating apoptosis-related genes expression. Reference: Med Sci Monit. 2018; 24: 6735–6741. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180944/
In vivo activity:
The impact of ferroptosis on the progression of NASH induced was demonstrated by methionine/choline-deficient diet (MCD) feeding for 10 days. Because iron overload promoted the progression from NAFLD to NASH, iron-chelating agent, DFO (deferoxamine mesylate), which binds free iron, and is widely used to treat iron overload-associated disease, was used.Ttreatment of DFO successfully inhibited NASH progression, as confirmed by decreased histopathologic lesions; serum levels of ALT, AST, hepatic lipid peroxidation–associated MDA; and GSH levels (Figure 3, A–D). In addition, treatment of DFO attenuated RSL-3–mediated exacerbation of NASH severity, in contrast to the results from Figures 1 and 2 (Figure 3, A–D). In accordance with these results, markedly lower lipid accumulation was seen in MCD-fed mice treated with DFO, compared with that in MCD-fed mice without DFO treatment, as revealed by Oil-red O staining and hepatic triglyceride levels (Figure 3, A, E, and F). In addition, treatment of DFO abrogated the RSL-3–mediated increment of lipid accumulation in MCD-fed mice (Figure 1, B, D, and F, and Figure 3, A, E, and F). Reference: Am J Pathol. 2020 Jan;190(1):68-81. https://pubmed.ncbi.nlm.nih.gov/31610178/
Solvent mg/mL mM
Solubility
DMSO 53.0 80.07
H2O 113.0 172.05
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 656.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wahl EA, Schenck TL, Machens HG, Balmayor ER. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Sci Rep. 2016 Nov 10;6:36879. doi: 10.1038/srep36879. PMID: 27830734; PMCID: PMC5103276. 2. Yang Y, Xu Y, Su A, Yang D, Zhang X. Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism. Med Sci Monit. 2018 Sep 24;24:6735-6741. doi: 10.12659/MSM.910325. PMID: 30246777; PMCID: PMC6180944. 3. Yang Y, Xu Y, Su A, Yang D, Zhang X. Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism. Med Sci Monit. 2018 Sep 24;24:6735-6741. doi: 10.12659/MSM.910325. PMID: 30246777; PMCID: PMC6180944.
In vitro protocol:
1. Wahl EA, Schenck TL, Machens HG, Balmayor ER. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Sci Rep. 2016 Nov 10;6:36879. doi: 10.1038/srep36879. PMID: 27830734; PMCID: PMC5103276. 2. Yang Y, Xu Y, Su A, Yang D, Zhang X. Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism. Med Sci Monit. 2018 Sep 24;24:6735-6741. doi: 10.12659/MSM.910325. PMID: 30246777; PMCID: PMC6180944.
In vivo protocol:
1. Qi J, Kim JW, Zhou Z, Lim CW, Kim B. Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice. Am J Pathol. 2020 Jan;190(1):68-81. doi: 10.1016/j.ajpath.2019.09.011. Epub 2019 Oct 11. Erratum in: Am J Pathol. 2020 Mar;190(3):723. PMID: 31610178. 2. Wahl EA, Schenck TL, Machens HG, Balmayor ER. VEGF released by deferoxamine preconditioned mesenchymal stem cells seeded on collagen-GAG substrates enhances neovascularization. Sci Rep. 2016 Nov 10;6:36879. doi: 10.1038/srep36879. PMID: 27830734; PMCID: PMC5103276.
1: Guillemot J, Asselin MC, Susan-Resiga D, Essalmani R, Seidah NG. Deferoxamine stimulates LDLR expression and LDL uptake in HepG2 cells. Mol Nutr Food Res. 2015 Nov 18. doi: 10.1002/mnfr.201500467. [Epub ahead of print] PubMed PMID: 26577249. 2: Rassu G, Salis A, Porcu EP, Giunchedi P, Roldo M, Gavini E. Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases. Carbohydr Polym. 2016 Jan 20;136:1338-47. doi: 10.1016/j.carbpol.2015.10.048. Epub 2015 Oct 23. PubMed PMID: 26572479. 3: Bellanti F, Del Vecchio GC, Putti MC, Cosmi C, Fotzi I, Bakshi SD, Danhof M, Della Pasqua O. Model-Based Optimisation of Deferoxamine Chelation Therapy. Pharm Res. 2015 Nov 10. [Epub ahead of print] PubMed PMID: 26555666. 4: Zhao J, Xi G, Wu G, Keep RF, Hua Y. Deferoxamine Attenuated the Upregulation of Lipocalin-2 Induced by Traumatic Brain Injury in Rats. Acta Neurochir Suppl. 2016;121:291-4. doi: 10.1007/978-3-319-18497-5_50. PubMed PMID: 26463963. 5: Choy W, Bohnen AM, Pelargos P, Lam S, Yang I, Smith ZA. Neurosurgery concepts: Key perspectives on deferoxamine and chronic hydrocephalus from intraventricular hemorrhage, laboratory dissection training in neurosurgical residency, tetanus toxoid and dendritic cell vaccines for glioblastoma, and intracranial hypertension after surgery for craniosynostosis. Surg Neurol Int. 2015 Aug 19;6:139. doi: 10.4103/2152-7806.163179. eCollection 2015. PubMed PMID: 26392916; PubMed Central PMCID: PMC4553661. 6: Darwish SF, El-Bakly WM, El-Naga RN, Awad AS, El-Demerdash E. Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy. Biochem Pharmacol. 2015 Nov 1;98(1):231-42. doi: 10.1016/j.bcp.2015.09.001. Epub 2015 Sep 7. PubMed PMID: 26358138. 7: Tada M, Niwano Y, Kohno M. Generation Mechanism of Deferoxamine Radical by Tyrosine-Tyrosinase Reaction. Anal Sci. 2015;31(9):911-6. doi: 10.2116/analsci.31.911. PubMed PMID: 26353957. 8: Choi CW, Lee J, Lee HJ, Park HS, Chun YS, Kim BI. Deferoxamine Improves Alveolar and Pulmonary Vascular Development by Upregulating Hypoxia-inducible Factor-1α in a Rat Model of Bronchopulmonary Dysplasia. J Korean Med Sci. 2015 Sep;30(9):1295-301. doi: 10.3346/jkms.2015.30.9.1295. Epub 2015 Aug 13. PubMed PMID: 26339170; PubMed Central PMCID: PMC4553677. 9: Mehrabani M, Najafi M, Kamarul T, Mansouri K, Iranpour M, Nematollahi MH, Ghazi-Khansari M, Sharifi AM. Deferoxamine preconditioning to restore impaired HIF-1α-mediated angiogenic mechanisms in adipose-derived stem cells from STZ-induced type 1 diabetic rats. Cell Prolif. 2015 Oct;48(5):532-49. doi: 10.1111/cpr.12209. PubMed PMID: 26332145. 10: Sorond FA, Tan CO, LaRose S, Monk AD, Fichorova R, Ryan S, Lipsitz LA. Deferoxamine, Cerebrovascular Hemodynamics, and Vascular Aging: Potential Role for Hypoxia-Inducible Transcription Factor-1-Regulated Pathways. Stroke. 2015 Sep;46(9):2576-83. doi: 10.1161/STROKEAHA.115.009906. Epub 2015 Jul 30. PubMed PMID: 26304864; PubMed Central PMCID: PMC4551113.